Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background And Aim: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.
Methods: We compared the impact of a dietary supplement protein complex (Cyplexinol) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.
Results: Pain and discomfort scores improved ( ≤ 0.05) for subjects following use of Cyplexinol but not placebo. Improvements were noted for WOMAC pain ( = 0.05), stiffness ( = 0.039), and total pain ( = 0.026), as well as VAS pain ( = 0.015), recreational activity interference ( = 0.023), mood interference ( = 0.012), and total pain ( = 0.024). A trend was noted for WOMAC physical function ( = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol ( = 0.01), with a similar increase noted for placebo ( = 0.022). A near doubling in TGF-β ( = 0.001) was noted for Cyplexinol. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions ( > 0.05).
Conclusions: Cyplexinol can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.
Relevance For Patients: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol, as we observed decreased pain and stiffness following treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339409 | PMC |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!